Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia (Nature Communications (2012) 3 (688) DOI: 10.1038/ncomms1681);MiR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia

Nature Communications

Volumn 3, Issue , 2012, Pages

  Li, Zejuan ^a   Huang, Hao ^a   Chen, Ping ^a   He, Miao ^a,f   Li, Yuanyuan ^a   Arnovitz, Stephen ^a   Jiang, Xi ^a   He, Chunjiang ^a   Hyjek, Elizabeth ^a   Zhang, Jun ^b   Zhang, Zhiyu ^c   Elkahloun, Abdel ^d   Cao, Donglin ^a,g   Shen, Chen ^a   Wunderlich, Mark ^e   Wang, Yungui ^h   Neilly, Mary Beth ^a   Jin, Jie ^h   Wei, Minjie ^f   Lu, Jun ⁱ   Valk, Peter J M ^j   Delwel, Ruud ^j   Lowenberg, Bob ^j   Le Beau, Michelle M ^a   Vardiman, James ^a   Mulloy, James C ^e   Zeleznik Le, Nancy J ^b   Liu, Paul P ^d   Zhang, Jiwang ^b   Chen, Jianjun ^a   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f CHINA MEDICAL UNIVERSITY   (China)

^g GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

^h ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MICRORNA; MICRORNA 196B; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; FAS PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MIRN196 MICRORNA, HUMAN; MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; PHENOTYPE; TUMOR SUPPRESSOR GENE; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; APOPTOSIS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL TRANSFORMATION; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; METABOLISM; NUCLEOTIDE SEQUENCE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEMATOPOIESIS; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84863283403     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16192     Document Type: Erratum

References (60)

1. Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833 (2007). (Pubitemid 350006257)
2. Slany, R. K. The molecular biology of mixed lineage leukemia. Haematologica 94, 984-993 (2009).
3. Zeisig, B. B. et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol. Cell. Biol. 24, 617-628 (2004). (Pubitemid 38057914)
4. Kroon, E. et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17, 3714-3725 (1998). (Pubitemid 28327389)
5. Roth, J. J., Crist, R. C. & Buchberg, A. M. Might as well face it: MLL's addicted to HOX. Blood 113, 2372-2373 (2009).
6. Wong, P., Iwasaki, M., Somervaille, T. C., So, C. W. & Cleary, M. L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 21, 2762-2774 (2007). (Pubitemid 350070722)
7. Kumar, A. R. et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood 113, 1756-1758 (2009).
8. Faber, J. et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113, 2375-2385 (2009).
9. Ayton, P. M. & Cleary, M. L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298-2307 (2003). (Pubitemid 37128644)
10. Kawagoe, H., Humphries, R. K., Blair, A., Sutherland, H. J. & Hogge, D. E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13, 687-698 (1999). (Pubitemid 29243618)
11. Thorsteinsdottir, U., Kroon, E., Jerome, L., Blasi, F. & Sauvageau, G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol. Cell. Biol. 21, 224-234 (2001).
12. Sitwala, K. V., Dandekar, M. N. & Hess, J. L. HOX proteins and leukemia. Int. J. Clin. Exp. Pathol. 1, 461-474 (2008).
13. Lawrence, H. J. et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia 13, 1993-1999 (1999).
14. Armstrong, S. A. et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30, 41-47 (2002).
15. Smith, L. L. et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 8, 649-662 (2011).
16. So, C. W., Lin, M., Ayton, P. M., Chen, E. H. & Cleary, M. L. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4, 99-110 (2003). (Pubitemid 37040826)
17. Bach, C. et al. Leukemogenic transformation by HOXA cluster genes. Blood 115, 2910-2918 (2010).
18. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531 (2004). (Pubitemid 38868508)
19. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
20. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005). (Pubitemid 40839734)
21. Xiao, C. & Rajewsky, K. MicroRNA control in the immune system: basic principles. Cell 136, 26-36 (2009).
22. Chen, J., Odenike, O. & Rowley, J. D. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10, 23-36 (2010).
23. Marcucci, G., Mrozek, K., Radmacher, M. D., Garzon, R. & Bloomfield, C. D. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117, 1121-1129 (2011).
24. Popovic, R. et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood 113, 3314-3322 (2009).
25. Chaubey, A. et al. Intrinsic requirement of microRNA in hox-based leukemia initiating cell maintenance. Blood 16: Abstract 4192 (2010).
26. Li, Z. et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl Acad. Sci. USA 105, 15535-15540 (2008).
27. Schotte, D. et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 95, 1675-1682 (2010).
28. Milne, T. A. et al. MLL associates specifically with a subset of transcriptionally active target genes. Proc. Natl Acad. Sci. USA 102, 14765-14770 (2005). (Pubitemid 41457130)
29. Milne, T. A., Martin, M. E., Brock, H. W., Slany, R. K. & Hess, J. L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65, 11367-11374 (2005). (Pubitemid 41821694)
30. Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368 (2008).
31. Erfurth, F. E. et al. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc. Natl Acad. Sci. USA 105, 7517-7522 (2008). (Pubitemid 351830050)
32. Kumar, A. R., Sarver, A. L., Wu, B. & Kersey, J. H. Meis1 maintains stemness signature in MLL-AF9 leukemia. Blood 115, 3642-3643 (2010).
33. Leung, A. K. & Sharp, P. A. MicroRNAs: a safeguard against turmoil? Cell 130, 581-585 (2007). (Pubitemid 47268068)
34. Vasudevan, S., Tong, Y. & Steitz, J. A. Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 1931-1934 (2007).
35. Mayr, C., Hemann, M. T. & Bartel, D. P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579 (2007). (Pubitemid 46449474)
36. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21, 1025-1030 (2007). (Pubitemid 46686471)
37. Mayr, C. & Bartel, D. P. Widespread shortening of 3 ' UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684 (2009).
38. Osborne, C. S. et al. Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J. Virol. 73, 5490-5496 (1999). (Pubitemid 29274832)
39. Pannell, D. et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J. 19, 5884-5894 (2000).
40. Wang, Y. et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol. Dis. 44, 191-197 (2010).
41. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001). (Pubitemid 32397092)
42. Wouters, B. J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113, 3088-3091 (2009).
43. Min, Y. H. et al. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br. J. Haematol. 93, 928-930 (1996). (Pubitemid 26199337)
44. Baryshnikov, A. et al. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv. Exp. Med. Biol. 457, 251-258 (1999). (Pubitemid 129735318)
45. Min, Y. J. et al. Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk. Res. 28, 359-365 (2004). (Pubitemid 38199943)
46. Suminoe, A. et al. mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an independent predictor for poor prognosis. Leukemia 18, 365-368 (2004). (Pubitemid 38240059)
47. Traver, D., Akashi, K., Weissman, I. L. & Lagasse, E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9, 47-57 (1998). (Pubitemid 28361294)
48. Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
49. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105 (2009).
50. Debernardi, S. et al. MicroRNA miR-181a correlates with morphological subclass of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 21, 912-916 (2007). (Pubitemid 46672066)
51. Mencia, A. et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat. Genet. 41, 609-613 (2009).
52. Yekta, S., Shih, I. H. & Bartel, D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594-596 (2004). (Pubitemid 38541919)
53. Arnold, C. P. et al. MicroRNA programs in normal and aberrant stem and progenitor cells. Genome Res. 21, 798-810 (2011).
54. Yekta, S., Tabin, C. J. & Bartel, D. P. MicroRNAs in the Hox network: an apparent link to posterior prevalence. Nat. Rev. Genet. 9, 789-796 (2008).
55. Bhatia, S., Kaul, D. & Varma, N. Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia. Mol. Cell. Biochem. 346, 103-116 (2011).
56. Bhatia, S., Kaul, D. & Varma, N. Potential tumor suppressive function of miR-196b in B-cell lineage acute lymphoblastic leukemia. Mol. Cell. Biochem. 340, 97-106 (2010).
57. Li, Y. et al. Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res. 70, 7894-7904 (2010).
58. Shaulian, E. AP-1-The Jun proteins: oncogenes or tumor suppressors in disguise? Cell. Signal. 22, 894-899 (2010).
59. Ferbeyre, G. & Moriggl, R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim. Biophys. Acta 1815, 104-114 (2011).
60. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006). (Pubitemid 44258912)